Advertisement

Sonoma Pharmaceuticals, Inc. SNOA

Set alert

Price alert · SNOA

All alert types
1.10 USD -0.10 -8.33%

At close · Oct 30

1.10 0.00 0.00%

After hours · Oct 30, 4:00 PM ET

Bid
1.07 × 2
Ask
1.10 × 2
1.07 Day range 1.17
1.01 52-week range 3.95
YTD
-69.78%
1 year
-72.15%
Open
1.16
Prev close
1.20
Mkt cap
5.27M
Vol
85.81K
Avg vol
106.86K
EPS
-1.22
P/E
0.00
Div yield
0.00%
More statistics
Low
1.07
High
1.17
Forward P/E
-1.49
Beta
1.38
Short ratio
0.22
Inst. own
2.42%
Dividend
0.00
Ex-div date
Earnings
Feb 13, 2025
50-d avg
2.82
200-d avg
3.79
1y target
19.50

5D chart

Chart tools
Interval

Signals (9)
NameTimeAgo
SMA: BearishOct 30, 9:30 AM1 day ago
MACD: Sell SignalOct 30, 9:30 AM1 day ago
MACD: Buy SignalOct 29, 3:55 PM2 days ago
MACD: Sell SignalOct 29, 2:30 PM2 days ago
SMA: BullishOct 29, 9:35 AM2 days ago
SMA: BearishOct 28, 3:55 PM3 days ago
SMA: BearishOct 28, 9:30 AM3 days ago
SMA: BearishOct 28, 9:30 AM3 days ago
SMA: BullishOct 26, 3:50 PM5 days ago

Key statistics

Market cap
3.59M
Enterprise value
569.36K
Trailing P/E
0.00
Forward P/E
-1.49
PEG ratio
0.00
Price / sales
0.28
Price / book
0.34
EPS (TTM)
-0.99
Beta
1.38
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-35.91%
Revenue (TTM)
12.70M
Revenue growth
-1.10%
Free cash flow
-1.70M
Total cash
2.59M
Total debt
420.00K
Return on equity
-74.65%
Shares outstanding
1.34M
Short % of float
6.06%
50-day average
2.82
200-day average
3.79

Analyst view

Consensus: none

Price target (mean) 19.50 +1672.7% upside
Target (low)
17.00
Target (mean)
19.50
Target (high)
22.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy1
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Feb 13, 2025

Expected Feb 13, 2025. Consensus EPS estimate -0.60.

Earnings history

Financials — quick view

All financials
SNOA Revenue — quarterly 6.41M
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
SNOA Net income — quarterly -330.00K
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026
SNOA EPS — quarterly -0.09
2023-Q2 20222023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 2026

Earnings

SNOA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 13, 2025Dec 1, 20240.00———
Nov 7, 2024Sep 1, 20240.00-0.59——
Aug 8, 2024Jun 1, 20240.00-1.40——
Jun 17, 2024Mar 1, 20240.00-1.40——
Feb 8, 2024Dec 1, 20230.00-1.20——
Nov 13, 2023Sep 1, 20230.00-4.00——

Upgrades / downgrades

SNOA analyst upgrades and downgrades
DateFirmActionFromTo
Sep 5, 2023Ladenburg Thalmanninit—Buy
Mar 6, 2018Maxim GroupdownBuyHold
Dec 28, 2017Benchmarkinit—Speculative Buy
Nov 10, 2017Maxim Groupmain—Buy

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on SNOA — it syncs with the Stock Master app.

Insider holders

SNOA insider holders
InsiderRelationLatest transactionDateShares held
DAL POGGETTO JOHNOfficerStock Award(Grant)Jun 19, 202415,000
DVONCH JEROME JChief Financial OfficerStock Award(Grant)Jun 19, 202484,595
THORNTON BRUCEOfficerStock Award(Grant)Jun 19, 2024154,411
TROMBLY AMY MOSSChief Executive OfficerStock Award(Grant)Jun 19, 2024153,586

Institution ownership

SNOA institution ownership
Holder% heldSharesValueReported
UBS Group AG0.95%12,73034.12KSep 29, 2024
Ground Swell Capital, LLC0.78%10,40027.87KSep 29, 2024
Tower Research Capital LLC (TRC)0.31%4,14111.10KSep 29, 2024
Citigroup Inc.0.01%180482Sep 29, 2024
JP Morgan Chase & Company0.01%138369Sep 29, 2024
Blackrock Inc.0.01%113302Sep 29, 2024

Fund ownership

SNOA fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.40%5,34214.32KOct 30, 2024
Fidelity Total Market Index Fund0.19%2,5286.78KOct 30, 2024
Fidelity Series Total Market Index Fund0.14%1,8815.04KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.02%248664Oct 30, 2024
Vanguard Extended Market Index Fund0.01%190509Sep 29, 2024
Advertisement